Objective: To develop and test model to predict outcome of treatment with initial lamotrigine monotherapy in adult patients with newly diagnosed localization - related epilepsy, using data available at the time of diagnosis.
Methods: Prospective longitudinal study included consecutive series of adult patients with newly diagnosed localization - related epilepsy started of lamotrigine monotherapy. Logistic regression analysis using backward procedure was performed with treatment failure as the outcome variable. We evaluated both calibration and discrimination of the model. Internal validation of the model was performed with bootstrapping techniques.
Results: A total of 159 patients on lamotrigine monotherapy have been included in final analysis. Among them 78 (49.06%) patients had persistent seizures. Finally fitted multivariate model included: 1) age at therapy start, 2) presence of complex partial seizures, 3) aetiology of epilepsy and 4) interaction of age and epilepsy aetiology. Estimated odds ratio for seizure relapse in old patients with symptomatic epilepsy is lower than for the old patients with cryptogenic epilepsy, despite strong positive covariate effect of epilepsy aetiology. The model correctly classified 69.23% patients with seizure relapses and 81.48% of patients with seizure freedom, with estimated c - statistic of 0.80. Testing practical application we observed threefold increase or reduction of odds for the seizure relapse after model's positive or negative prediction respectively.
Conclusion: Standard clinical data were modesty adequate to predict response to the initial trial of lamotrigine in adult patients with localization related epilepsy. Better markers of antiepileptic failure are required to guide optimal patient counselling and clinical decisions. Formal interaction analysis of variables improves outcome prediction and may be a key to correct interpretation of data.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eplepsyres.2013.11.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy (DEE) characterized by multiple types of drug-resistant seizures (which must include tonic seizures) with classical onset before 8 years (although some cases with later onset have also been described), abnormal electroencephalographic features, and cognitive and behavioral impairments. Management and treatment of LGS are challenging, due to associated comorbidities and the treatment resistance of seizures. A panel of five epileptologists reconvened to provide updated guidance and treatment algorithms for LGS, incorporating recent advancements in antiseizure medications (ASMs) and understanding of DEEs.
View Article and Find Full Text PDFEffect of antiepileptic drug monotherapy on endogenous sex hormonal profile in men and women with epilepsy.
Epilepsy Behav
December 2024
Council of Scientific and Industrial Research -Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi 110007, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:
Objective: To assess the alterations of endogenous sex hormone profiles in patients with epilepsy (PWE) on different antiepileptic drug (AED) monotherapies compared to healthy controls and drug naïve PWE (DNPWE).
Methods: Four databases MEDLINE, EMBASE, SCOPUS, and CENTRAL were searched for analytical observational/intervention studies on the assessment of endogenous sex hormones in PWE compared to healthy controls and DNPWE. Two researchers reviewed the title/abstract, and full-text articles for the selection of the studies independently.
Assessment of temporal changes in cognitive effects induced by antiseizure medications in epilepsy patients.
Epilepsy Behav
December 2024
Liv Hospital Neurology Department, Kavaklıdere, Bestekar Cd No:8, 06680 Cankaya, Ankara, Turkey.
Objective: Numerous studies have been conducted investigating the effects of antiseizure medications (ASMs) on cognitive functions, and the cognitive side effects of some ASMs have been demonstrated. However, data on whether tolerance to these side effects develops over time is insufficient. The aim of this study is to evaluate the reversibility of cognitive impairments caused by ASMs in patients, utilizing event-related potentials (ERPs) and the Montreal Cognitive Assessment (MoCA) test.
View Article and Find Full Text PDFTrends of antiseizure medication utilization among pregnant people in four Canadian provinces from 1998 to 2023; a study from the Canadian mother-child cohort active surveillance initiative (CAMCCO).
Front Pharmacol
November 2024
College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Article Synopsis
- The study examines the use of antiseizure medications (ASMs) among pregnant individuals in four Canadian provinces over 20 years, focusing on trends and patterns in ASM usage among those with and without epilepsy.
- Results showed that only 0.7% of the pregnant population had epilepsy, with 1.7% exposed to ASMs; notable increases in ASM use were observed among those without epilepsy, especially in Manitoba, Saskatchewan, and Alberta.
- The analysis also revealed shifts in ASM drug classes, with a decline in older medications like carbamazepine and a rise in newer options like lamotrigine, while usage patterns varied by province and trimester.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!